Sterile Inflammatory Pain
Conditions
Interventions
Dexamethasone Palmitate Group:The drug formulation is as follows: 2% lidocaine 1 mL + 1 mL dexamethasone palmitate, with an injection volume of 0.5–1 mL based on the patients condition.
Compound betamethasone group:The drug formulation is as follows: 2% lidocaine 1 mL + 1 mL compound betamethasone, with an injection volume of 0.5–1 mL based on the patients condition.
Sponsors
Shenzhen Nanshan People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Age <= 18 years, regardless of gender; (2) Patients meet the diagnostic criteria for chronic pain in limbs and joints (based on the definitions of chronic pain categories in the International Classification of Diseases, ICD-11), with etiology consistent with one of the following conditions: ? Soft tissue sterile inflammation: myofascial pain syndrome, tendinitis, bursitis/synovitis (e.g., popliteal cyst, tenosynovitis, lateral epicondylitis, scar pain), rotator cuff disorders (e.g., frozen shoulder, subacromial impingement syndrome, piriformis syndrome), etc. ? Pain related to osteoarticular diseases: Periarthritis of the knee, periarthritis of the hip, arthritis of the fingers, sacroiliitis, temporomandibular joint arthritis, etc. (3) Patients are only required to undergo minimally invasive administration of long-acting corticosteroids (combined with local anesthetics and long-acting corticosteroids) for treatment; (4) Patients without active infectious diseases; (5) Participants must agree to participate in the study and provide written informed consent.
Exclusion criteria
Exclusion criteria: (1)Patients allergic to the medications specified in the protocol; (2)Patients with infection at the injection site; (3)Patients with severe hematologic disorders; (4)Patients with immunosuppression due to tumors or severe infections; (5)Patients with hypercortisolism; (6)Patients with severe heart failure, renal failure, or respiratory failure; (7)Patients with poorly controlled blood pressure (systolic blood pressure >160 mmHg, diastolic blood pressure >100 mmHg); (8)Patients with glaucoma or posterior capsular cataracts; (9)Patients who have not recovered from visceral surgery or have post-surgical complications; (10)Patients with peptic ulcers; (11)Patients with electrolyte metabolic disorders; (12)Patients with poorly controlled blood glucose (HbA1c >8.5%, fasting blood glucose >8.5 mmol/L, or 2-hour postprandial blood glucose >13.9 mmol/L); (13)Patients with mental disorders or inability to cooperate with medication and examinations; (14)Breastfeeding, pregnant, or potentially pregnant women; (15)Patients who have participated in any clinical drug trials within the past three months. (16) the patient is unwilling to participate in the clinical trial; (17) Other conditions that the investigator considers unsuitable for this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Numerical rating scale;Health Assessment Questionnaire;Pittsburgh Sleep Quality Index (PSQI);Hamilton Depression Rating Scale (HAMD);Hamilton Anxiety Rating Scale (HAMA);Fingerstick blood glucose;Hemoglobin A1c (HbA1c); | — |
Countries
China
Contacts
Public ContactXiang Liao
Shenzhen Nanshan People's Hospital
Outcome results
None listed